Metastatic Cholangiocarcinoma as a Target of Molecular-Directed Therapy

Abstract

It is reported a unique clinical case of administration of crizotinib in a 14-year-old patient with ALK-positive metastatic cholangiocarcinoma and congenital viral hepatitis B. Driver oncogenic mutations potentially responsive to targeted therapy as well as possible ways to prolong crizotinib short-term effect are discussed.